Cellebrite DI Valuation
Is CLBT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CLBT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CLBT ($19.89) is trading above our estimate of fair value ($19.8)
Significantly Below Fair Value: CLBT is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CLBT?
Key metric: As CLBT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is CLBT's PS Ratio? | |
|---|---|
| PS Ratio | 11.3x |
| Sales | US$385.17m |
| Market Cap | US$4.35b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 10.2x |
| Enterprise Value/EBITDA | 58.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CLBT's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.7x | ||
AI C3.ai | 14.2x | 18.4% | US$4.6b |
IDCC InterDigital | 6.9x | -14.0% | US$5.0b |
BL BlackLine | 6x | 8.3% | US$3.9b |
WK Workiva | 7.6x | 14.9% | US$5.5b |
CLBT Cellebrite DI | 11.3x | 14.0% | US$4.3b |
Price-To-Sales vs Peers: CLBT is expensive based on its Price-To-Sales Ratio (11.3x) compared to the peer average (8.7x).
Price to Sales Ratio vs Industry
How does CLBT's PS Ratio compare vs other companies in the US Software Industry?
Price-To-Sales vs Industry: CLBT is expensive based on its Price-To-Sales Ratio (11.3x) compared to the US Software industry average (5.5x).
Price to Sales Ratio vs Fair Ratio
What is CLBT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 11.3x |
| Fair PS Ratio | 6.6x |
Price-To-Sales vs Fair Ratio: CLBT is expensive based on its Price-To-Sales Ratio (11.3x) compared to the estimated Fair Price-To-Sales Ratio (6.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$19.89 | US$22.43 +12.8% | 5.3% | US$24.00 | US$21.00 | n/a | 7 |
| Nov ’25 | US$18.53 | US$19.86 +7.2% | 12.2% | US$23.00 | US$17.00 | n/a | 7 |
| Oct ’25 | US$16.52 | US$19.14 +15.9% | 13.2% | US$23.00 | US$17.00 | n/a | 7 |
| Sep ’25 | US$17.06 | US$18.00 +5.5% | 7.3% | US$20.00 | US$17.00 | n/a | 7 |
| Aug ’25 | US$13.39 | US$14.36 +7.2% | 6.6% | US$16.00 | US$13.00 | n/a | 7 |
| Jul ’25 | US$12.14 | US$14.36 +18.3% | 6.6% | US$16.00 | US$13.00 | n/a | 7 |
| Jun ’25 | US$10.65 | US$14.36 +34.8% | 6.6% | US$16.00 | US$13.00 | n/a | 7 |
| May ’25 | US$10.75 | US$13.64 +26.9% | 9.3% | US$16.00 | US$12.00 | n/a | 7 |
| Apr ’25 | US$11.01 | US$13.75 +24.9% | 9.8% | US$16.00 | US$12.00 | n/a | 6 |
| Mar ’25 | US$12.29 | US$13.17 +7.1% | 8.1% | US$15.00 | US$12.00 | n/a | 6 |
| Feb ’25 | US$9.21 | US$10.17 +10.4% | 8.8% | US$12.00 | US$9.00 | n/a | 6 |
| Jan ’25 | US$8.66 | US$10.17 +17.4% | 8.8% | US$12.00 | US$9.00 | n/a | 6 |
| Dec ’24 | US$8.42 | US$10.00 +18.8% | 11.5% | US$12.00 | US$8.00 | n/a | 6 |
| Nov ’24 | US$6.85 | US$9.83 +43.6% | 12.3% | US$12.00 | US$8.00 | US$18.53 | 6 |
| Oct ’24 | US$7.65 | US$9.83 +28.5% | 12.3% | US$12.00 | US$8.00 | US$16.52 | 6 |
| Sep ’24 | US$8.18 | US$9.83 +20.2% | 12.3% | US$12.00 | US$8.00 | US$17.06 | 6 |
| Aug ’24 | US$7.76 | US$8.21 +5.8% | 20.8% | US$11.00 | US$6.50 | US$13.39 | 6 |
| Jul ’24 | US$7.20 | US$7.65 +6.3% | 16.7% | US$10.00 | US$6.50 | US$12.14 | 5 |
| Jun ’24 | US$5.74 | US$7.53 +31.2% | 18.4% | US$10.00 | US$6.15 | US$10.65 | 5 |
| May ’24 | US$5.49 | US$7.53 +37.2% | 18.4% | US$10.00 | US$6.15 | US$10.75 | 5 |
| Apr ’24 | US$6.09 | US$7.48 +22.8% | 19.2% | US$10.00 | US$5.90 | US$11.01 | 5 |
| Mar ’24 | US$5.75 | US$7.38 +28.3% | 20.1% | US$10.00 | US$5.90 | US$12.29 | 5 |
| Feb ’24 | US$5.51 | US$7.10 +28.9% | 24.6% | US$10.00 | US$5.00 | US$9.21 | 5 |
| Jan ’24 | US$4.36 | US$7.50 +72.0% | 18.9% | US$10.00 | US$6.00 | US$8.66 | 5 |
| Dec ’23 | US$4.69 | US$7.50 +59.9% | 18.9% | US$10.00 | US$6.00 | US$8.42 | 5 |
| Nov ’23 | US$4.74 | US$7.70 +62.4% | 20.0% | US$10.00 | US$6.00 | US$6.85 | 5 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Bitdeer Technologies Group
US$1.6b
Operates as a technology company for blockchain and computing.
BTDR
US$12.23
7D
2.9%
1Y
160.2%
Capgemini
€25.9b
Engages in the provision of consulting, digital transformation, technology, and engineering services primarily in North America, France, the United Kingdom, Ireland, the rest of Europe, the Asia-Pacific, and Latin America.
CAPM.F
€156.80
7D
-3.8%
1Y
-24.4%
ACI Worldwide
US$6.0b
A software company, develops, markets, installs, and supports a range of software products and solutions for facilitating digital payments in the United States and internationally.
ACIW
US$56.66
7D
3.5%
1Y
108.7%